BREAK COVID: COVID-19 breakthrough infections and correlates of protectio

Recruiting

• Conditions: coronavirus; COVID-19; 10047438

• Registration Number: NL-OMON53358
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 550

Inclusion Criteria

Over 18 years of age
Willing to share vaccination and infection records with the investigators

Exclusion Criteria

Not fulfilling the inclusing criteria

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Cellular and humoral correlates of protection from symptomatic and<br /><br>asymptomatic SARS-CoV-2 breakthrough infection after vaccination<br /><br>2, Cellular and humoral correlates of protection from symptomatic and<br /><br>asymptomatic infection after natural infection</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Risk of symptomatic BTI after booster vaccination, and after natural<br /><br>infection, with the in 2023 predominating SARS-CoV-2 variant.<br /><br>2. Risk of asymptomatic BTI after booster vaccination, and after natural<br /><br>infection, with the in 2023 predominating SARS-CoV-2 variant<br /><br>3. Other factors associated with BTI (variants, vaccine regimen;<br /><br>monovalent/bivalent, nasal transcriptome findings over time prior, during and<br /><br>14 days after infection, immune status)</p><br>